Jun 2026 (Q2 FY26) — Aug 6, 2026
Shoulder Innovations Q2 FY26 — Strong Revenue Growth and Accelerated Product Pipeline
Read the full callShoulder Innovations (SI) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Shoulder Innovations earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 17.2 | +56.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -58.4 | −5.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -10.2 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$18.37 +2.80% · +$0.5
Performance +47.2% 1Y
1Y: $12.48 on 14 Oct 2025 → $18.37. High $24.25 (28 Jul 2026), low $11.01 (10 Nov 2025).
- Previous close
- $17.87
- 52-week range
- $11.01 – $24.25
- One year
- +51.69%
Overview
- Symbol
- SI
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Shoulder Innovations earnings calls (SI)
Financials
What the filings say
Net profit, year on year: +47% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 7 | 9 | 10 | 11 | 12 | 14 | 17 | 17 |
| Operating profit | -4 | -4 | -4 | -6 | -8 | -8 | -9 | -10 |
| Operating margin | −52.1% | −40.5% | −42.4% | −53.2% | −65.0% | −59.0% | −53.7% | −58.4% |
| Other income | -0 | -0 | -0 | -13 | -1 | 1 | 1 | -0 |
| Interest | 0 | 0 | 0 | 0 | 0 | -1 | -0 | -1 |
| Profit before tax | -4 | -4 | -5 | -19 | -9 | -8 | -8 | -10 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net profit | -4 | -4 | -5 | -19 | -9 | -8 | -8 | -10 |
| EPS ($ per share) | -68.31 | — | -52.13 | -165.53 | -0.64 | — | -0.41 | -0.49 |
| Line item | Dec 2024 | Dec 2025 |
|---|---|---|
| Equity capital | 0 | 0 |
| Reserves | -57 | -97 |
| Total liabilities | 23 | 29 |
| Fixed assets | 7 | 13 |
| Total assets | 43 | 170 |
| Line item | Dec 2024 | Dec 2025 |
|---|---|---|
| Cash from operations | -14 | -29 |
| Cash from investing | 14 | -96 |
| Cash from financing | 0 | 145 |
| Capital expenditure | -4 | -7 |
| Free cash flow | -18 | -36 |
Insider filings
49 filings between Dec 11, 2025 and Oct 5, 2026.
Open market
decisions to buy or sellPurchases
$214.9K
7 purchases by 3 insiders
Sales
$5.47M
17 sales by 3 insiders
35% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 13
- Award — granted as compensation
- 9
- Option exercise — converted options into shares
- 2
- Tax withheld — shares kept back by the company to cover tax
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Gilde Healthcare Holding B.V. | — | $4.44M | Aug 26, 2026 |
| Ahearn Matthew Fraser | — | $839.1K | Aug 18, 2026 |
| Ball Robert Joseph | $140.4K | $187.7K | Sep 14, 2026 |
| Points Jeffrey S. | $59.6K | — | Mar 13, 2026 |
| Buchholz Richard | $14.8K | — | Mar 13, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Sidow Kevin K. Director | Award | 892 | $17.5K |
| Oct 5, 2026 | Tansey Casey M Director | Award | 733 | $14.4K |
| Oct 5, 2026 | BUCKMAN PAUL Director | Award | 1,275 | $25.0K |
| Oct 5, 2026 | Hykes Andrew Director | Award | 669 | $13.1K |
| Sep 14, 2026 | Ball Robert Joseph CEO & Executive Chairman | Sale | 10,175 | $187.7K |
| Sep 14, 2026 | Ball Robert Joseph CEO & Executive Chairman | Option exercise | 89,233 | $187.3K |
| Aug 26, 2026 | Gilde Healthcare Holding B.V. 10% owner | Sale | 1,196 | $27.0K |
| Aug 24, 2026 | Gilde Healthcare Holding B.V. 10% owner | Sale | 681 | $15.4K |
| Aug 21, 2026 | Gilde Healthcare Holding B.V. 10% owner | Sale | 20,516 | $463.9K |
| Aug 20, 2026 | Gilde Healthcare Holding B.V. 10% owner | Sale | 3,900 | $88.1K |
| Aug 18, 2026 | Ahearn Matthew Fraser Chief Operating Officer | Sale 10b5-1 plan | 1,600 | $34.2K |
| Aug 18, 2026 | Ahearn Matthew Fraser Chief Operating Officer | Sale 10b5-1 plan | 12,586 | $263.5K |
| Aug 17, 2026 | Ahearn Matthew Fraser Chief Operating Officer | Sale 10b5-1 plan | 8,314 | $167.1K |
| Aug 14, 2026 | Ahearn Matthew Fraser Chief Operating Officer | Gift 10b5-1 plan | 2,500 | $0 |
| Aug 6, 2026 | Gilde Healthcare Holding B.V. 10% owner | Sale | 2,095 | $47.3K |
| Aug 5, 2026 | Gilde Healthcare Holding B.V. 10% owner | Sale | 7,338 | $166.1K |
| Aug 4, 2026 | Gilde Healthcare Holding B.V. 10% owner | Sale | 99,812 | $2.27M |
| Aug 3, 2026 | Gilde Healthcare Holding B.V. 10% owner | Sale | 10,751 | $244.2K |
| Jul 31, 2026 | Gilde Healthcare Holding B.V. 10% owner | Sale | 20,034 | $455.4K |
| Jul 30, 2026 | Gilde Healthcare Holding B.V. 10% owner | Sale | 28,245 | $659.8K |
| Jun 26, 2026 | Sidow Kevin K. Director | Award | 5,046 | $0 |
| Jun 26, 2026 | BUCKMAN PAUL Director | Award | 5,046 | $0 |
| Jun 26, 2026 | Tansey Casey M Director | Award | 5,046 | $0 |
| Jun 26, 2026 | Buchholz Richard Director | Award | 5,046 | $0 |
| Jun 26, 2026 | Hykes Andrew Director | Award | 5,046 | $0 |
| Jun 15, 2026 | Ahearn Matthew Fraser Chief Operating Officer | Sale 10b5-1 plan | 1,644 | $29.9K |
| Jun 15, 2026 | Ahearn Matthew Fraser Chief Operating Officer | Sale 10b5-1 plan | 2,500 | $48.1K |
| Jun 12, 2026 | Ahearn Matthew Fraser Chief Operating Officer | Sale 10b5-1 plan | 15,856 | $296.2K |
| Apr 30, 2026 | Ball Robert Joseph CEO & Executive Chairman | Option exercise | 10,000 | $24.8K |
| Apr 20, 2026 | Ahearn Matthew Fraser Chief Operating Officer | Option exercise | 7,421 | $18.4K |
| Apr 20, 2026 | Ahearn Matthew Fraser Chief Operating Officer | Option exercise | 14,243 | $40.8K |
| Mar 13, 2026 | Ball Robert Joseph CEO & Executive Chairman | Purchase | 2,200 | $33.4K |
| Mar 13, 2026 | BUCKMAN PAUL Director | Tax withheld | 3,714 | $55.0K |
| Mar 13, 2026 | Points Jeffrey S. Chief Financial Officer | Option exercise | 13,264 | $32.9K |
| Mar 13, 2026 | Points Jeffrey S. Chief Financial Officer | Purchase | 2,000 | $30.0K |
| Mar 13, 2026 | Buchholz Richard Director | Purchase | 1,000 | $14.8K |
| Mar 13, 2026 | BUCKMAN PAUL Director | Tax withheld | 3,292 | $48.1K |
| Mar 13, 2026 | BUCKMAN PAUL Director | Option exercise | 26,205 | $55.0K |
| Mar 13, 2026 | BUCKMAN PAUL Director | Option exercise | 19,401 | $48.1K |
| Feb 6, 2026 | Ball Robert Joseph CEO & Executive Chairman | Option exercise | 10,000 | $24.8K |
| Feb 6, 2026 | Ball Robert Joseph CEO & Executive Chairman | Option exercise | 2,062 | $4.3K |
| Dec 31, 2025 | Ball Robert Joseph CEO & Executive Chairman | Award | 1,661 | $20.2K |
| Dec 31, 2025 | Blue David Lawrence See Remarks | Award | 1,041 | $12.7K |
| Dec 31, 2025 | Points Jeffrey S. Chief Financial Officer | Award | 1,076 | $13.1K |
| Dec 31, 2025 | Ahearn Matthew Fraser Chief Operating Officer | Award | 477 | $5.8K |
| Dec 12, 2025 | Ball Robert Joseph CEO & Executive Chairman | Purchase | 3,900 | $58.1K |
| Dec 12, 2025 | Points Jeffrey S. Chief Financial Officer | Purchase | 1,005 | $15.1K |
| Dec 11, 2025 | Points Jeffrey S. Chief Financial Officer | Purchase | 995 | $14.6K |
| Dec 11, 2025 | Ball Robert Joseph CEO & Executive Chairman | Purchase | 3,300 | $48.9K |
| Sep 12, 2025 | Blue David Lawrence SEE REMARKS | Option exercise | 78,616 | $165.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for SHOULDER INNOVATIONS, INC.
Free account. Everything above stays public.
Write why you follow SHOULDER INNOVATIONS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading